C19 Therapeutics

C19 Therapeutics is a biotechnology company focused on developing novel therapeutic interventions to combat COVID-19 and its associated complications. The company's research and development efforts are centered on identifying and optimizing small molecule inhibitors and monoclonal antibodies that target critical viral proteins and host inflammatory pathways. By addressing both the viral replication cycle and the hyper-inflammatory response seen in severe cases, C19 Therapeutics aims to provide comprehensive treatment options for patients. Their pipeline includes early-stage programs targeting the SARS-CoV-2 main protease and various pro-inflammatory cytokines.